Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;32(10):1076-1082.
doi: 10.1007/s11606-017-4084-0. Epub 2017 Jun 9.

Substance Use Disorder Treatment Following Clinician-Initiated Discontinuation of Long-Term Opioid Therapy Resulting from an Aberrant Urine Drug Test

Shannon M Nugent  1   2   3 , Steven K Dobscha  4   5 , Benjamin J Morasco  4   5 , Michael I Demidenko  4 , Thomas H A Meath  4   6 , Joseph W Frank  7   8 , Travis I Lovejoy  4   5   9
Affiliations

Substance Use Disorder Treatment Following Clinician-Initiated Discontinuation of Long-Term Opioid Therapy Resulting from an Aberrant Urine Drug Test

Shannon M Nugent et al. J Gen Intern Med. 2017 Oct.

Abstract

Background: It is unclear whether substance use disorder (SUD) treatment is offered to, or utilized by, patients who are discontinued from long-term opioid therapy (LTOT) following aberrant urine drug tests (UDTs).

Objective: To describe the proportion of patients who were referred to, and engaged in, SUD treatment following LTOT discontinuation and to examine differences in SUD treatment referral and engagement based on the substances that led to discontinuation.

Design: From a sample of 600 patients selected from a national cohort of Veterans Health Administration patients who were discontinued from LTOT, we used manual chart review to identify 169 patients who were discontinued because of a UDT that was positive for alcohol, cannabis, or other illicit or non-prescribed controlled substances.

Main measures: We extracted sociodemographic, clinical, and health care utilization data from patients' electronic medical records.

Key results: Forty-three percent of patients (n = 73) received an SUD treatment referral following LTOT discontinuation and 20% (n = 34) engaged in a new episode of SUD treatment in the year following discontinuation. Logistic regression models controlling for sociodemographic and clinical variables demonstrated that patients who tested positive for cannabis were less likely than patients who tested positive for non-cannabis substances to receive referrals for SUD treatment (aOR = 0.44, 95% CI = 0.23-0.84, p = 0.01) or engage in SUD treatment (aOR = 0.42, 95% CI = 0.19-0.94, p = 0.04). Conversely, those who tested positive for cocaine were more likely to receive an SUD treatment referral (aOR = 3.32, 95% CI = 1.57-7.06, p = 0.002) and engage in SUD treatment (aOR = 2.44, 95% CI = 1.00-5.96, p = 0.05) compared to those who did not have a cocaine-positive UDT.

Conclusions: There may be substance-specific differences in clinician referrals to, and patient engagement in, SUD treatment. This suggests a need for more standardized implementation of clinical guidelines that recommend SUD care, when appropriate, following LTOT discontinuation.

Keywords: chronic pain; long-term opioid therapy; physician referral; substance use treatment.

PubMed Disclaimer

Conflict of interest statement

Disclaimer

The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the US Department of Veterans Affairs or US Government.

Conflict of Interest

The authors declare that they do not have a conflict of interest.

Figures

Fig. 1
Fig. 1
Sample selection for patients who discontinued long-term opioid therapy (LTOT).
See this image and copyright information in PMC

Comment in

References

    1. Institute of Medicine . Relieving pain in America: A blueprint for transforming prevention, care, education, and research. Washington: The National Academies Press; 2011. - PubMed
    1. Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain. 2015;16(8):769–780. doi: 10.1016/j.jpain.2015.05.002. - DOI - PMC - PubMed
    1. Deyo RA, Von Korff M, Duhrkoop D. Opioids for low back pain. BMJ. 2015;350:g6380. doi: 10.1136/bmj.g6380. - DOI - PMC - PubMed
    1. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624–1645. doi: 10.1001/jama.2016.1464. - DOI - PMC - PubMed
    1. Brennan PL, Del Re AC, Henderson PT, Trafton JA. Healthcare system-wide implementation of opioid-safety guideline recommendations: the case of urine drug screening and opioid-patient suicide- and overdose-related events in the Veterans Health Administration. Trans Behav Med. 2016;6(4):605–612. doi: 10.1007/s13142-016-0423-7. - DOI - PMC - PubMed

Substances

LinkOut - more resources